Long-term Safety of Aficamten for Hypertrophic Cardiomyopathy
Recruiting1 awardPhase 2 & 3
San Francisco, California
This trial is focused on collecting data about the safety and tolerability of a new medication called aficamten. The study involves people who are using this medication to see if it remains safe and well-tolerated over an extended period.
Intracardiac Echocardiography for Hypertrophic Cardiomyopathy
Recruiting1 award1 criteria
New York, New York
This trial is investigating whether or not a new intraoperative echocardiography technique called OPIE is as effective as traditional methods in measuring the thickness of the left ventricular septum in patients with hypertrophic cardiomyopathy.
Popular Filters
Trials for HCM Patients
Behavioural Intervention
myPACE+ Algorithm for Hypertrophic Cardiomyopathy
Recruiting1 award3 criteria
Bronx, New York
This trial will study patients with a heart condition called nHCM and specific symptoms. The study will compare two groups of patients with different pacing methods. The researchers believe that the personalized accelerated pacing method will
Myosin Inhibitor
Aficamten for Pediatric Hypertrophic Cardiomyopathy
Recruiting0 awardsPhase 2 & 3
Morristown, New Jersey
"This trial aims to see how well aficamten works, how safe it is, and how the body processes it in children with a type of heart condition called obstructive hypertrophic cardiomyopathy
Myosin Inhibitor
EDG-7500 for Hypertrophic Cardiomyopathy
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial aims to investigate the safety and impact of different amounts of EDG-7500 in adults with a heart condition called obstructive hypertrophic cardiomyopathy, by giving either one dose or multiple
Phase 3 Trials
Myosin Inhibitor
Aficamten for Pediatric Hypertrophic Cardiomyopathy
Recruiting0 awardsPhase 2 & 3
Morristown, New Jersey
"This trial aims to see how well aficamten works, how safe it is, and how the body processes it in children with a type of heart condition called obstructive hypertrophic cardiomyopathy
Myosin Inhibitor
Mavacamten for Hypertrophic Cardiomyopathy
Recruiting1 awardPhase 3
La Jolla, California
This trial is testing a new medication called mavacamten to see if it is safe and effective for people with a heart condition that makes their heart muscle too thick. The goal is to help their heart work better and improve their symptoms.
Aficamten for Hypertrophic Cardiomyopathy
Recruiting1 awardPhase 3
Anchorage, Alaska
This trial is testing aficamten, a medication that may help people with a thickened heart muscle condition. It aims to improve their quality of life and ability to exercise. The drug works by making the heart muscle less stiff, which could help the heart pump blood better.
Myosin Inhibitor
Aficamten vs Metoprolol for Hypertrophic Cardiomyopathy
Recruiting1 awardPhase 3
Anchorage, Alaska
This trial compares a new drug, aficamten, with a common heart medication, metoprolol succinate, in adults with a specific heart condition that causes symptoms and blood flow blockage. Aficamten helps the heart muscle relax, while metoprolol succinate slows and eases the heart's pumping. Metoprolol has been widely used since 1975.
Trials With No Placebo
Behavioural Intervention
myPACE+ Algorithm for Hypertrophic Cardiomyopathy
Recruiting1 award3 criteria
Bronx, New York
This trial will study patients with a heart condition called nHCM and specific symptoms. The study will compare two groups of patients with different pacing methods. The researchers believe that the personalized accelerated pacing method will
Myosin Inhibitor
EDG-7500 for Hypertrophic Cardiomyopathy
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial aims to investigate the safety and impact of different amounts of EDG-7500 in adults with a heart condition called obstructive hypertrophic cardiomyopathy, by giving either one dose or multiple
Behavioral Intervention
Exercise Program for Hypertrophic Cardiomyopathy
Recruiting1 award6 criteria
San Francisco, California
This trial will compare the effects of moderate exercise vs. usual activity on improving symptoms and cardiac function in people with HCM. 70 participants will be monitored over 24 weeks.
Procedure
SESAME Procedure for Hypertrophic Cardiomyopathy
Recruiting1 award
Atlanta, Georgia
"This trial is testing a new procedure called SESAME in adults with a condition where the heart's pumping chambers are separated by a thick wall. This thick wall can cause reduced blood flow and serious heart disease
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.